Advertisement

Click here for more guidelines.

 
 




CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2005; 45:1368-1369, doi:10.1016/j.jacc.2005.02.016
© 2005 by the American College of Cardiology Foundation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Estes, N.A. M.
Right arrow Articles by Virmani, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Estes, N.A. M., III
Right arrow Articles by Virmani, R.

36TH BETHESDA CONFERENCE: TASK FORCES

Task Force 9: Drugs and performance-enhancing substances

N.A. Mark Estes, III, MD, FACC, Chair, Robert Kloner, MD, PhD, FACC, Brian Olshansky, MD, FACC and Renu Virmani, MD, FACC



    General considerations
 Top
 General considerations
 Appendix 1
 References
 
Athletes commonly use drugs and dietary supplements because they hope to improve athletic performance. These performance-enhancing substances include ergogenic and thermogenic supplements, stimulants, anabolic steroids, peptide hormones, and others. Despite aggressive marketing and user testimonials, scientific studies assessing the benefits and risks of any of these substances have not been conducted (1–5). Clinical observations indicate some supplements may have serious side effects including fatal adverse reactions (6–8). Athletes should make informed decisions regarding the use of drugs and dietary supplements with careful consideration of what is known and unknown. Health care professionals should ask about drug and dietary supplements and serve as an educational resource for athletes and athletic organizations (9).

Many drugs and supplements are marketed to improve exercise duration or physical strength, to shorten recovery time from exertion, to reduce fat, or in other ways to improve athletic performance (1–3,10–13). These substances include anabolic-androgenic steroids and the more than 30 natural and synthetic derivatives including tetrahydrogestrinone (THG). Androstenedione, commonly referred to as "andro," and dehydroepiandrosterone (DHEA) are available in oral form and are sold as nutritional supplements. Stimulants include amphetamines, cocaine, dexadrine, ephedra, ritalin, beta-2 agonists, and others (1–3,10–13). Peptide hormones and analogues, such as recombinant erythropoietin (EPO), are used as a pharmacologic alternative to "blood doping" or autotransfusion (1–3,10–13). Human growth hormone (hCG), chorionic gonadotropin, pituitary and synthetic gonadotropins (LH), and corticotropins (ACTH, tetracosactide) also are used because they are believed to improve athletic performance (1–3,10–13).

Dietary supplements are products, other than tobacco, containing vitamins, minerals, amino acids, herbs, or other botanical dietary substances (1–3,10–13). Some substances such as vitamins, minerals, bee pollen, caffeine, glycine, carnitine, lecithin, brewer’s yeast, gelatin, creatine, protein supplements, and others probably have minimal toxicity when used in recommended doses. Based on serious concerns regarding the safety of a popular energy drink with taurine, caffeine, and glucuronolactone, multiple European countries have banned its sale (10). Like most dietary supplements this drink has not been assessed for efficacy or toxicity in rigorous scientific studies (1–3,10–13).

Other banned drugs that are not considered performance-enhancing would come under the designation of recreational drugs (1–5,13). These include alcohol, cannaboids, sedatives, narcotics, LSD, and others that have the potential to impair cognitive and physical function and are prohibited (1–3,12,13). The dietary supplement ephedra (ma huang) is associated with life-threatening toxicity and death resulting on a ban of its sale by the Food and Drug Administration (6–8). Inadequate labeling and insufficient quality control in the production of many nutritional supplements are also reasons to recommend that athletes not take dietary supplements. Contamination or poor labeling of nutritional supplements are not regarded as adequate defenses by athletic governing bodies. Recognizing that there may be exceptional circumstances where an athlete will require an otherwise prohibited substance for medical purposes, formal therapeutic exemption mechanisms are available with prior consideration and approval (11–13).

Athletic governing bodies should provide comprehensive lists of prohibited drugs and dietary supplements (1,11–13). They should develop a rigorous approach to prevent performance-enhancing and recreational drug and dietary supplement use. The crucial elements of any program should include education, counseling, treatment, detection, and enforcement. Governing athletic bodies should use all available resources to enhance, supplement, and coordinate existing efforts to educate athletes and reinforce the ethical principles inherent in athletic participation. Without such oversight, the integrity of athletics is threatened. Ultimately, athletes must accept responsibility for the decisions they make regarding the usage of drugs and performance-enhancing substances.

Athletes taking or considering the use of such substances should be aware that the safety and efficacy of supplements used for improving athletic performance have not been addressed in systematic scientific studies. Trainers, exercise physiologists, sports nutritionists, athletic governing bodies, or medical organizations should discourage the use of dietary supplements by athletes. Serious side effects may result from the use of these substances, including cardiac hypertrophy, myocyte necrosis, myocarditis, fibrosis, coronary thrombosis, and sudden death (even at recommended dosing) (2,3,6–8,10).

Recommendation:

1 Athletes should have their nutritional needs met through a healthy, balanced diet without dietary supplements.


    Appendix 1
 Top
 General considerations
 Appendix 1
 References
 


View this table:
[in this window]
[in a new window]
 
Author Relationships With Industry and Others
 

    References
 Top
 General considerations
 Appendix 1
 References
 
1. Estes III NAM, Link MS, Cannom D, et al. Report of the NASPE policy conference on arrhythmias and the athlete J Cardiovasc Electrophysiol 2001;12:1208-1219.[CrossRef][Web of Science][Medline]

2. Kloner RA. Illicit drug use in the athlete as a contributor to cardiac eventsIn: Estes III NAM, Salem D, Wang P, editors. Sudden Cardiac Death in the Athlete. Armonk, NY: Futura Pub. Co; 1998. pp. 441-452.

3. Cregler LL. Substance abuse in sportsthe impact of cocaine, alcohol, steroids, and other drugs on the heart. In: Williams R, editor. The Athlete and Heart Disease. Diagnosis, Evaluation and Management. Philadelphia, PA: Lippincott Williams & Wilkins; 1998. pp. 131-154.

4. DeAngelis CD, Fontanarosa PB. Drugs alias dietary supplements JAMA 2003;290:1519-1520.[Free Full Text]

5. Stout CW, Weinstock J, Homoud MK, Wang PJ, Estes III NAM, Link MS. Herbal medicinebeneficial effects, side effects, and promising new research in the treatment of arrhythmias. Curr Cardiol Rep 2003;5:395-401.[Medline]

6. Samenuk D, Link MS, Homoud MK, et al. Adverse cardiovascular events temporally associated with ma huang, an herbal source of ephedrine Mayo Clin Proc 2002;77:12-16.[Abstract/Free Full Text]

7. U.S. Food and Drug Administration FDA announces plans to prohibit sale of dietary supplements containing ephedra. 2003December 30, Available at: http://www.fda.gov/oc/initiatives/ephedra/february2004/. Accessed October 1, 2004..

8. U.S. Food and Drug Administration. RAND report. Available at: http://www.fda.gov/OHRMS/DOCKETS/98fr/95n-0304-bkg0003- ref-07-01-index.htm. Accessed October 1, 2004..

9. Maron BJ, Thompson PD, Puffer JC, et al. Cardiovascular preparticipation screening of competitive athletesa statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young), American Heart Association. Circulation 1996;94:850-856.[Free Full Text]

10. Ireland to review safety of energy drinks. Available at: http://www.foodanddrinkeurope.com/news/ng.asp?id=49957. Accessed October 1, 2004..

11. The National Center for Drug Free Sport, Inc. Nutritional supplements. http://www.drugfreesport.com/choices/supplements/index.html. Accessed October 1, 2004..

12. NCAA Web site. Drug testing policy. Available at: http://www1.ncaa.org/membership/ed_outreach/health-safety/drug_testing/index.html. Accessed October 1, 2004..

13. World Anti-Doping Agency. Available at: http://www.wada-ama.org. Accessed November 30, 2004..




This article has been cited by other articles:


Home page
Br. J. Sports. Med.Home page
M Borjesson and A Pelliccia
Incidence and aetiology of sudden cardiac death in young athletes: an international perspective
Br. J. Sports Med., September 1, 2009; 43(9): 644 - 648.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. J. Maron and A. Pelliccia
The Heart of Trained Athletes: Cardiac Remodeling and the Risks of Sports, Including Sudden Death
Circulation, October 10, 2006; 114(15): 1633 - 1644.
[Full Text] [PDF]


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Estes, N.A. M.
Right arrow Articles by Virmani, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Estes, N.A. M., III
Right arrow Articles by Virmani, R.

 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement